Against the background of these contradictory reports, and the yet unknown role of MED10 in BLCA, the present study investigated the probable role of dysregulated or aberrantly expressed MED10 in the enhanced onco-aggression, disease progression, and recurrence of bladder UC, as well as the underlying molecular mechanism. The gene discussed is MED10; the disease is bladder transitional cell carcinoma.